Clinical Trial Search

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 13.5; 13.5 Percentage of participants

Primary: To Evaluate Efficacy of RAD001 as Monotherapy for the Treatment of Papillary Renal Cancer. Efficacy is Defined as the Percentage of Patients Progression-free at 6…

Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants

Primary: Objective Response Rate (RECIST Version 1.1) — 0; 0; 3; 8 Participants

Primary: PFS (Progression-Free Survival) — 27.71 Weeks

Primary: Overall Response Rate — 72; 35 Percentage of participants

Primary: Response Rate — 8 Participants

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: Overall Response Rate — 27 percentage of patients

Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023

Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Duration of Sunitinib and Pazopanib Treatment in Participants — 171; 114.5 days

Primary: Progression Free Survival (PFS) — 2.7; 5.2 months

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Metabolic Response — 5 participants

Primary: Progression-free Survival — 12 Weeks

Primary: Anti-tumor Activity as Measured by Median Progression Free Survival Time — 5.6; 8.3 Months — p=0.157

Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Progression-free Survival (PFS) — 8.4; 9.5 Months

Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) — 78; 27 participants

Primary: Overall Response by RECIST Criteria — 3; 75; 101; 24 participants

Primary: Toxicities Measured Using CTCAE Version 4.03 — 4 participants with G3 TRAEs

Primary: Initial Objective Response- First Participation — 5; 1; 7; 4 Participants

Primary: Follow-up Duration — 1.07 years

Primary: Number of Participants With Preference for Pazopanib Versus Sunitinib as Assessed by the Patient Preference Questionnaire (PPQ) — 19; 6; 37; 43 participants — p=<0.001